Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years

Alsughayer, Anas; Dabbagh, Tamara Z.; Abdel-Razeq, Rashid; Al-Jussani, Ghada N.; Alhassoon, Salam; Sughayer, Maher A.

doi:10.1200/go.21.00359

Cited by 4 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most prevalent histomorphologic type of BC in the current study is NST, accounting for 84% of the cases. A similar finding is reported in Ethiopia and other countries (19,25,27,38,41,(49)(50)(51)(52).…”

Section: Discussionsupporting

confidence: 85%

Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia

Belachew,

Desta,

Gebremariam

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

PurposeDifferent biological characteristics, therapeutic responses, and disease-specific outcomes are associated with different molecular subtypes of breast cancer (BC). Although there have been different studies on BC in the Ethiopian capital city of Addis Ababa, there have been few studies in other parts of the nation, and none have evaluated biological characteristics in other locations in the context of the extensive ethnic and genetic diversity found in Ethiopia. This study was carried out to evaluate the distribution of immunohistochemistry (IHC) subtypes of BCs throughout four Ethiopian regions.MethodsA total of 227 formalin-fixed paraffin-embedded (FFPE) tissue blocks were collected from tertiary hospitals in four Ethiopian regions between 2015 and 2021. The IHC staining was performed for subtyping, ER, PR, HER2, and Ki-67 proliferation markers.ResultsThe mean age at diagnosis was 43.9 years. The percentage of ER and PR-negative tumors were 48.3% and 53.2%, respectively. The IHC subtypes showed the following distribution: 33.1% triple-negative breast cancer (TNBC), 27.6% luminal B, 25.2% luminal A, and 14.1% HER2 enriched. In multiple logistic regression analysis, grade III and HER2 positivity were associated with larger tumor size, and also originating from Jimma compared to Mekele.ConclusionPatients with ER-negative, PR-negative, and TNBC were found in 48.3%, 53.2%, and 33.1% of cases, respectively, showing that half the patients could potentially benefit from endocrine treatment. A considerably high prevalence of TNBC was reported in our study, demanding additional research that includes genetic predisposition factors. Additionally, aggressive tumors were found in a high percentage of younger age groups, which must be considered when planning personalized treatment strategies.

show abstract

Section: Discussionsupporting

confidence: 85%

Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia

Belachew,

Desta,

Gebremariam

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Estrogen receptor (E receptor), progesterone receptor (P receptor), human epidermal growth factor 2 (HER factor (2), and Ki67 are common biological factors related to the prognosis of IBC. E receptors and P receptors are a family of steroid hormones that regulate the transcription of target genes after binding to receptors and can promote malignant breast hyperplasia [6]. HER factor 2 can induce the increase of vascular endothelial growth factor in the body, furthermore promoting the formation of tumor angiogenesis, and is closely related to tumor proliferation, invasion, and metastasis [7].…”

Section: Introductionmentioning

confidence: 99%

[Retracted] Correlation Analysis of Ultrasound Elastography Score with Invasive Breast Cancer and Biological Prognostic Factors

Wan

Qin

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Invasive breast cancer (IBC) is a kind of malignant tumor in which cancer cells have broken through the basement membrane of breast ducts or lobular acini and invaded the stroma. Although ultrasound elastography score (UES) has shown unique advantages in the diagnosis of IBC, its value in the prognosis is not clear. Here, we explored the correlation of UES with IBC and biological prognostic factors. The datum of 86 patients with suspected IBC from January 2018 to December 2021 was collected. UE was applied in the examination of all patients. The lesion tissue of the malignant group was punctured to detect and analyze the expression of biological prognostic factors, including estrogen receptor (E receptor), progesterone receptor (P receptor), and human epidermal growth factor 2 (HER factor 2) and Ki67. The differences in UES under different biological prognostic factors were compared. The receiver operating characteristic (ROC) curve was applied to analyze the diagnostic value of UES of IBC and the expression of biological prognostic factors. Based on the pathological diagnosis results, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of UES in the diagnosis of IBC were analyzed. The correlation of UES with IBC and biological prognostic factors was analyzed by multiple linear regression and Spearman method. ROC analysis showed that the area under the curve of UES for diagnosing IBC and evaluating the expression of P receptor, HER factor 2, and Ki67 were 0.877, 0.704, 0.763, and 0.820, respectively (P＜0.05). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of UES when diagnosing IBC were 92.42%, 90.00%, 91.86%, 96.83%, and 78.26%, respectively. The UES of E receptor expression (positive and negative group) showed no obvious variance ( P > 0.05). The UES of P receptors (positive and negative), HER factor 2 (positive and negative), and Ki67 (high and low expression) showed obvious differences ( P < 0.05). Multiple linear regression and Spearman indicated UES was significantly correlated with the expression of P receptor, HER factor 2, and Ki67 (P＜0.05). UES has a certain diagnostic value for IBC and is significantly correlated to the expression of P receptor, HER factor 2, and Ki67, which is helpful for evaluating the prognosis of patients with IBC.

show abstract

“…Invasive BC is primarily categorized into four molecular subtypes using immunohistology analysis, based on the expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [9][10][11]. Luminal A BC, which is positive for either or both ER and PR and negative for HER2, accounts for 50-60% of BC cases and generally has a favorable prognosis [12,13].…”

Section: Introductionmentioning

confidence: 99%

Unveiling the genetic landscape: high frequency of pik3ca mutation in luminal a and b breast cancer within the Indonesian population

Prajoko,

Heriyanto,

Amalina

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Breast cancer (BC) is a global health concern with significant mortality rates, necessitating a deep understanding of its molecular landscape. Objective: This study focuses on the prevalence of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations in Luminal A and B BC within the Indonesian population. Luminal A and B BC, characterized by estrogen receptor (ER) and/or progesterone receptor (PR) positivity, face challenges in endocrine therapy due to acquired resistance, often mediated by PI3K/Akt/mTOR pathway activation. Methods: The study, conducted from 2019 to 2022, collected samples from diverse Indonesian regions, representing various islands. Histopathological analysis and immunohistochemistry classified samples into molecular subtypes. Results: Genetic analysis using PIK3CA mutation detection kits revealed a mutation frequency of 36.2%, with Luminal A BC exhibiting the highest mutation rate (46.1%). Notably, Luminal B HER-2 (positive) BC demonstrated a lower mutation frequency (19%). Statistical analyses highlighted correlations between PIK3CA mutations and molecular subtypes (p=0.01), with Luminal A and Luminal B HER-2 (negative) BC showing higher mutation frequencies. No significant associations were observed with age, tumor location, or histopathology diagnosis. Luminal A BC demonstrated a higher prevalence of PIK3CA mutations in patients over 50 years old (68.1%). Comparisons with existing literature and inconsistencies in PIK3CA mutation prevalence across different BC subtypes underline the need for population-specific research. Conclusion: The study emphasizes the importance of assessing PIK3CA mutations in BC management, offering insights for personalized therapies and potential advancements in understanding this complex disease within the Indonesian context.

show abstract

Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years

Cited by 4 publications

References 45 publications

Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia

Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia

[Retracted] Correlation Analysis of Ultrasound Elastography Score with Invasive Breast Cancer and Biological Prognostic Factors

Unveiling the genetic landscape: high frequency of pik3ca mutation in luminal a and b breast cancer within the Indonesian population

Contact Info

Product

Resources

About